Evidence map›Paper›PMID 40453069›Full record

ArticleFrontiers in immunology2025

Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology.

Xinyao Zhou, Wuqian Wang, Luan Chen, Yingjun Yang, Xing Wei, Jia Zhou, Kuan Sun, Ping Tang, Xiaofang Sun, Shengying Qin and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Xinyao ZhouDepartment of Fetal Medicine & Prenatal Diagnosis Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Wuqian WangDepartment of Obstetrics and Gynecology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Luan ChenBio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.
Yingjun YangDepartment of Obstetrics, Center of Fetal Medicine & Intrauterine Pediatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xing WeiDepartment of Fetal Medicine & Prenatal Diagnosis Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Jia ZhouDepartment of Fetal Medicine & Prenatal Diagnosis Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Kuan SunDepartment of Fetal Medicine & Prenatal Diagnosis Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Ping TangJiaxing Maternity and Children Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, Zhejiang, China.
Xiaofang SunDepartment of Obstetrics and Gynecology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Shengying QinBio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China.
Luming SunDepartment of Obstetrics, Center of Fetal Medicine & Intrauterine Pediatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Effective intrauterine treatments for placental-mediated fetal growth restriction (FGR) remain limited, necessitating reliable protein biomarkers for early diagnosis and management. Methods: In this study, we analyzed differential protein expression in peripheral blood plasma samples from 44 placental-mediated FGR patients and 44 normal pregnant women using the Olink-Explore-384-Inflammation panel. The analysis identified significant differences in protein expression levels, followed by enrichment analyses to explore the underlying biological mechanisms. Protein-protein interaction (PPI) network analysis and Least Absolute Shrinkage and Selection Operator (LASSO) modeling were used to identify key proteins as potential biomarkers. Results: We identified 225 proteins with significantly altered expression between FGR patients and normal pregnancies. Proteins such as Placental Growth Factor (PGF) and Hepatocyte Growth Factor (HGF) were previously found to be strongly associated with FGR. In addition, we discovered novel proteins potentially associated with FGR, including ESM1 and TIMP3. Enrichment analyses revealed that several pathways, including placental dysfunction, inflammatory responses, and oxidative stress, may play crucial roles in FGR pathophysiology. PPI network analysis further identified key proteins such as ANGPT2, CD40, and HGF, as potentially linked to FGR. LASSO modeling validated PGF and ESM1 as important biomarkers. Additionally, integrating a multi-protein panel with blood flow disruption analysis significantly improved diagnostic accuracy. Conclusion: Our findings provide valuable insights into the molecular mechanisms of FGR, identifying key proteins as potential biomarkers. The multi-protein panel model offers a promising tool for early screening and diagnosis of FGR.

Indexed as

BiomarkersFetal Growth RetardationPlacentaProteomicsAdultFemaleHumansPlacenta Growth FactorPregnancyProtein Interaction MapsBiomarkersPlacenta Growth Factorbiomarkersfetal growth restriction (FGR)Olink proteomics platformproximity extension assay (PEA)targeted proteomics analysis

Identifiers

PMID40453069
PMCPMC12123377

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.